Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED BALANCE SHEETS

v3.25.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Jun. 30, 2024
Current Assets:    
Cash and cash equivalents $ 162,186 $ 151,791
Short-term available-for-sale investments   1,072
Accounts receivable, less allowances of $4,215 and $4,386, respectively 206,876 241,394
Inventories 189,446 179,731
Current assets held-for-sale 12,332 9,773
Other current assets 37,460 33,658
Total current assets 608,300 617,419
Property and equipment, net 245,719 251,154
Right-of-use assets 73,399 91,285
Goodwill 980,935 972,663
Intangible assets, net 365,599 507,081
Deferred tax asset 10,307  
Other assets 273,609 264,265
Total assets 2,557,868 2,703,867
Current liabilities:    
Trade accounts payable 25,311 37,968
Salaries, wages and related accruals 65,791 49,818
Accrued expenses 25,663 24,886
Contract liabilities 32,571 27,930
Income taxes payable 10,770 3,706
Operating lease liabilities - current 14,098 12,920
Other current liabilities 1,645 2,151
Total current liabilities 175,849 159,379
Deferred income taxes 6,169 55,863
Long-term debt obligations 346,000 319,000
Operating lease liabilities 83,960 87,618
Other long-term liabilities 27,082 13,157
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 154,972,196 and 158,216,258 respectively 1,550 1,582
Additional paid-in capital 911,089 820,337
Retained earnings 1,066,049 1,325,247
Accumulated other comprehensive loss (59,880) (78,316)
Total Bio-Techne's shareholders' equity 1,918,808 2,068,850
Total liabilities and shareholders' equity $ 2,557,868 $ 2,703,867